 The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Companys study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18, 2023 GLOBE NEWSWIRE SciSparc Ltd. Nasdaq: SPRC Company or SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been... The post SciSparc Receives Approval to Conduct its Clinical Trial... 